Vaccines: mRNA vaccine technology - Cancer, COVID-19 & beyond

Det Norske Videnskaps-Akademi, Drammensveien 78, Oslo

Møtet er fulltegnet.

Lecture by Professor Dr. Med. Özlem Türeci Chief Medical Officer, BioNTech

and Professor at Mainz University Medical Ctr & Helmholtz Institute for Translational Oncology

In her talk Türeci will describe the mRNA vaccine technology, how it was developed for cancer, adapted for COVID19 and how its use is now now being expanded to negelected infectious diseases.


Foredragsholder 16 november 2023
Özlem Türeci

Praktisk informasjon

Møtet er nå fulltegnet.

Dette Akademimøtet strømmes, se nederst på siden!




Innleder 16. november 2023
Agnete B. Fredriksen






Comments by:
Agnete Brunsvik Fredriksen
, Chief Business Officer & Co-founder of Nykode Therapeutic: "Taking vaccines one step further; controlling the immune response profile against the antigen"

Agnete B. Fredriksen is Co-Founder & Chief Business Officer of Nykode Therapeutics. She holds a MSc, PhD from Institute of Immunology, Rikshospitalet Medical Center in Oslo where she designed the first Vaccibody vaccines. Agnete is one of the inventors of the Vaccibody technology and served as CSO of Nykode for 14 years creating innovative, modular vaccines and moving these into clinical development. This has led to several clinical products and strong partnerships with Genentech and Regeneron. Agnete is currently responsible for the corporate strategy, business development and investor relations. She also serves as a member of the Board of Directors of Molecular Partners.  

John-Arne Røttingen (Wellcome Trust)
John-Arne Røttingen

John-Arne Røttingen, Ambassador for Global Health at The Norwegian Ministry of Foreign Affairs: "The importance of multi-country clinical trials in health emergencies"

John-Arne Røttingen is Ambassador for Global Health, Ministry of Foreign Affairs, Norway. He is Adjunct Scientific Director at the Norwegian Institute of Public Health and Visiting Fellow of Practice at Blavatnik School of Government, Oxford University. He has been founding CEO of CEPI (Coalition for Epidemic Preparedness Innovations); Chief Executive, Research Council of Norway; Executive Director of Infection Control and Environmental Health, Norwegian Institute of Public Health; Professor of Health Policy, University of Oslo; and Adjunct Professor, Department of Global Health and Population, Harvard T.H. Chan School of Public Health. He is member of The Norwegian Academy of Science and Letters and the US National Academy of Medicine. He holds MD PhD from University of Oslo, MSc from Oxford University and MPA from Harvard University.

Innleder på møte 16. november
Richard Hatchett

Richard J. Hatchett, MD: "Partnering to create the global vaccine library”

Richard J. Hatchett, MD, is Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations, or CEPI – a global partnership that supports the swift development of and equitable access to new vaccines and other defenses against infectious diseases with epidemic and pandemic potential. Dr Hatchett’s and CEPI’s plan is for the world to neutralize those pandemic threats with prescient investment in scientific R&D. Before taking on the CEPI leadership just after its launch in 2017, Dr Hatchett was Acting Director of the U.S. Biomedical Advanced Research and Development Authority (BARDA). He has also served under two U.S. Presidents – George W. Bush and Barack Obama – as Director of Medical Preparedness Policy on the Homeland and National Security Councils. Dr Hatchett has a medical degree from Vanderbilt and completed clinical training in internal medicine and medical oncology at Cornell and Duke.